Our intelligent technology mines EHR data
to find and diagnose rare disease patients
within your population. We monetize
EHR data for the benefit of the patient
and the Healthcare System.
The biggest problem in rare disease is the
5-8 Year diagnostic odyssey that rare
disease patients suffer through. We created
a compliant way for Biotech to sponsor and
fund the discovery & diagnosis of patients
so we can end the diagnostic odyssey.
We drive the discovery & diagnosis of targeted rare disease patients. We combine clinical and data science in our platform to mine the phenotype rich EHR data to discover rare disease patients
By helping providers identify patients and biotech identify providers, we create a short list of probable patients, and shorten the diagnostic odyssey of rare disease patients
Substantive, incremental, recurring revenue for the benefit of the patient. Nothing to purchase, no labor, no promises. Just Data, and in return your providers get insight & knowledge they didn't have and your patients benefit.
The hardest part of the process for Biotech is finding which providers have rare and ultra rare disease patients. Providers don’t have the tools to always know they have rare disease patients
No Software Purchase, No Fees, No Cost to Healthcare, Just Incremental, Substantive, Recurring Revenue
Our systems for data exchange, data storage and data management are HIPAA and HITECH compliant.
By creating new and incremental revenue streams and aligning incentives, through the safe harbor of RDDT and our management and execution of targeted searches, we can accelerate their discovery and bring an end to the odyssey
Our unique market model empowers collaboration, execution and funding of a process that benefits everyone, particularly patients.
Rare Disease < 200,000 Patients in the U.S.
Ultra Rare < 10,000 Patients in the U.S.
Because of complexity of diagnosis and heterogeneity of presentation, patients on average suffer a 5-8 year diagnostic odyssey, seeing as many as 8 providers, 4 specialist & suffering frequent mis-diagnosis
Rare disease is: Low rate of diagnosis & High level of importance to biotech; Low number of therapeutic options & High unmet medical need. Low volume of patients & High cost of therapy. Low disease and therapy awareness & High risk patients
Providers are under-trained in rare diseases, and healthcare systems are not equipped to look for or manage these special patients. Through our network of Biotech companies, we can bring an army of experts and support into play
Because patient populations are so small, manufacturers are able to charge high dollar amounts for therapies, making the discovery of patients very valuable to biotech
80% of rare diseases are genetically linked. These patients have an aggressive disease that is progressively killing them while going un-diagnosed and untreated. We can do better
They will never see any patient data and no access to PHI. RDDT will manage and execute the entire process. Healthcare is our primary partner and we will manage the process in a patient first manner
Biotech gets only high value Provider leads, No Patient Data, Just Providers with highly probable Rare Disease Patients. Instead of knocking on a 100 doors to find 2 patients, they can knock on just 2. Saving time and increasing efficiency for everyone
In order to ensure the purity of the process, Health Systems & Providers will be blinded to the sponsor of the targeted rare disease searches
Nashville, Tennessee, United States